Kinetics of hematopoietic stem cell migration in mice after severe mechanical trauma

1982 ◽  
Vol 93 (5) ◽  
pp. 593-595
Author(s):  
V. K. Kulagin ◽  
V. N. Aleksandrov
Keyword(s):  
Stem Cell ◽  
Cell Migration ◽  
Hematopoietic Stem Cell ◽  
Mechanical Trauma ◽  
Hematopoietic Stem ◽  
Stem Cell Migration ◽  
Kinetics Of

The role of endothelium in the regulation of hematopoietic stem cell migration

Stem Cells ◽  
2009 ◽  
Vol 16 (S2) ◽  
pp. 159-165 ◽  
Author(s):  
Robert Möhle ◽  
Malcolm A. S. Moore ◽  
Shahin Rafii
Keyword(s):  
Stem Cell ◽  
Cell Migration ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Stem Cell Migration

scholarly journals ROLE OF MACROPHAGES IN REGULATION OF HEMATOPOIETIC STEM CELL MIGRATION IN BONE MARROW PERIPHERAL BLOOD SYSTEM

2014 ◽  
Vol 12 (1-2) ◽  
pp. 7
Author(s):  
B. G. Yushkov ◽  
I. G. Danilova ◽  
I. A. Pashnina ◽  
I. A. Brykina ◽  
M. T. Abidov
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Cell Migration ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Blood System ◽  
Hematopoietic Stem ◽  
Stem Cell Migration

The GEF Lsc Regulates Hematopoietic Stem Cell Motility, Mobilization and Recruitment.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1346-1346
Author(s):  
Isabelle Petit ◽  
Prashant Kaul ◽  
Daniel J. Lerner ◽  
Shahin Rafii
Keyword(s):  
Stem Cell ◽  
Cell Migration ◽  
Tumor Growth ◽  
Cell Motility ◽  
Progenitor Cells ◽  
Hematopoietic Stem Cell ◽  
Tumor Angiogenesis ◽  
Progenitor Cell ◽  
Hematopoietic Stem ◽  
Stem And Progenitor Cells

Abstract Lsc is a Rho GTPase guanine nucleotide exchange factor (RhoGEF) that physically and functionally links G-protein coupled receptors (GPCR) to the monomeric GTPase RhoA in mature hematopoietic and other cells. Lsc−/− (LscKO) mice have a peripheral leukocytosis, abnormal neutrophil and B cell motility, and immune response deficiencies. Although Lsc is required for neutrophil homeostasis, its role in hematopoietic stem and progenitor cells is unknown. In this study, we have used LscKO mice to determine if Lsc is required for normal stem cell motility and mobilization. Initially, we used immunofluorescence labeling to demonstrate that hematopoietic stem and progenitor cells express Lsc. This suggested that Lsc may be required for normal hematopoietic stem and progenitor cell migration. Stromal-cell derived factor-1 (SDF-1) is a potent chemokine for hematopoietic stem cells and activates the CXCR4 GPCR. It has been reported that Lsc is not required for SDF-1-stimulated migration of mature murine T and B cells. However, using a bare-filter transwell assay, we found that while LscKO Sca-1+ cells and Sca-1+Lin- cells have normal spontaneous migration, they have significantly increased SDF-1-stimulated migration compared to their wild-type (WT) counterparts, 1.4 and 2.3 fold, respectively. We then demonstrated that adhesion of LscKO Sca-1+ cells to bone marrow (BM) stromal MS-5 cells was normal, indicating that impaired adhesion was not responsible for the abnormal SDF-1-stimulated migration. Using colony assay, we demonstrated that LscKO mice have a normal number of circulating peripheral stem and progenitor cells. Strikingly, after 5 days of G-CSF administration, LscKO mice have 1.6 fold and 2.3 fold the number of peripheral mature WBC and stem and progenitor cells (colony forming units), respectively, compared to WT mice. Recruitment of BM CXCR4+ pro-angiogenic stem and progenitor cells has been linked to enhanced tumor angiogenesis. Because LscKO BM cells had abnormal SDF-1-stimulated migration and mobilization, we hypothesized that Lsc might regulate tumor angiogenesis as well. To this end, we assessed tumor growth in LscKO mice by injecting congenic Lewis lung carcinoma cells subcutaneously into LscKO mice and WT controls. Preliminary experiments revealed that tumors were 3.3 times larger in the LscKO mice as compared to WT mice. Quantification of the tumor vessels with anti-CD31 staining demonstrated that the tumors in LscKO mice were 1.4 fold more vascularized than controls. In summary, our results demonstrate that the Rho GEF Lsc is essential for normal hematopoietic stem cell migration and mobilization. In addition, we propose that absence of Lsc facilitates tumor growth by promoting BM stem and progenitor cell recruitment to the neo-angiogenic vessels, possibly augmenting tumor vascularization.

Characterization of TPO Kinetics within 60 Days of Allogeneic Hematopoietic Stem Cell Transplantation and Its Correlation with Megakaryocyte Ploidy Distribution

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4463-4463
Author(s):  
Xiao-hui Zhang ◽  
Hai-xia Fu ◽  
Dai-Hong Liu ◽  
Lan-Ping Xu ◽  
Kai-Yan Liu ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Distribution Pattern ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Flow Cytometric Analysis ◽  
Hematopoietic Stem ◽  
Platelet Recovery ◽  
Kinetics Of

Abstract Abstract 4463 Background: Thrombocytopenia is a critical complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), but its pathogenesis has remained obscure. Thrombopoietin (TPO) has been identified as a key cytokine for both megakaryogenesis and thrombopoiesis; however, the kinetics of TPO production after allo-HSCT has not been reported. This study characterized the kinetics of TPO and its correlation with the megakaryocyte ploidy distribution pattern within 60 days of allo-HSCT. Methods and Results: A total of 46 consecutive patients who underwent allo-HSCT from October 2008 to December 2008 were included in the study. The TPO levels and the ploidy distribution pattern of MKs were measured using ELISA and flow cytometric analysis, respectively. The results indicate that the TPO levels and the platelet counts followed opposite trends after allo-HSCT. Multivariate analysis indicate that endogenous TPO levels before allo-HSCT, and the number of transplanted CD34+ cells were significant predisposing factors for rapid platelet engraftment (P=0.010 and 0.007, respectively). Furthermore, we found a reduction of ploidy and an increase in immature MKs in patients with higher endogenous TPO levels (> 250 pg/ml) on day 60 after allo-HSCT. Moreover, lower TPO levels (≤250 pg/ml) on day 60 after allo-HSCT were associated with significantly improved 2-year OS (P=0.032) and reduced TRM (P=0.026). Conclusion: Our results suggest that increased endogenous TPO levels may not be sufficient after allo-HSCT, and that the decreased ability of TPO may account for the appearance of antibodies. The use of exogenous rhTPO may promote platelet recovery after allo-HSCT. However, these possibilities need to be examined further. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document